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Abstract
Complement is a key first line innate host defense system in the blood of vertebrates. Upon 
activation, this powerful defense mechanism can elicit inflammatory responses, lyse non-self-cells, 
or mark them for opsonophagocytic removal. Blood-feeding arthropods thus require the ability to 
block host complement activation in the bloodmeal to prevent undesired cell or tissue damage 
during feeding. The soft tick Ornithodoros moubata produces a complement inhibitory protein, 
OmCI. This protein binds to a mammalian complement protein C5 and blocks further activation of 
complement cascades, which results in the prevention of complement-mediated bacterial killing 
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through membrane attack complex. Interestingly, the amino acids involved in OmCI binding are 
highly conserved among mammalian and avian C5, but the ability of this protein to inhibit the 
complement from birds remains unclear. Here we demonstrated that OmCI is capable of 
preventing quail complement-mediated erythrocyte lysis, inhibiting the capability of this animal’s 
complement to eliminate a serum-sensitive Lyme disease bacterial strain. We also found that the 
ability of OmCI to inhibit quail complement-mediated killing of Lyme disease bacteria can be 
extended to different domestic and wild birds. Our results illustrate the utility of OmCI to block 
bird complement. These results provide the foundation for further use of this protein as a tool to 
study the molecular basis of avian complement and pathogen evasion to such a defense 
mechanism.
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1. Introduction
The complement system is composed of a group of proteins, that function as the first line of 
host defense in the blood of vertebrates in response to invading pathogens (Meri, 2016; 
Trouw et al., 2017; Zipfel and Skerka, 2009). Complement is activated on the surface of the 
pathogen by three pathways: the classical, lectin, and alternative pathways (Meri, 2016; 
Trouw et al., 2017; Zipfel and Skerka, 2009). Activation of the classical pathway (initiated 
by antibody-bacterial antigen complexes) and the lectin pathway (initiated by lectin-
microbial carbohydrate complexes) results in the formation of C3 convertase, C4b2a. 
Activation of the alternative pathway (initiated by the interaction of C3b with the microbial 
surface) triggers the formation of C3 convertase, C3bBb. These C3 convertases recruit the 
complement protein C3b; addition of a C3b molecule to C3 convertases results in formation 
of the C5 convertases, C4b2a3b, and C3bBb3b. The C5 convertases then cleave C5 to C5a 
and C5b to release the anaphylatoxin C5a that attracts neutrophils, monocytes, and mast 
cells to induce inflammatory responses. C5b assembles with C6, C7, C8, and C9, resulting 
in the formation of a pore-forming membrane attack complex (MAC or C5b-9) on the 
pathogen surfaces to cause lysis.
When complement is not properly controlled, those complement complexes can be formed 
on the surface of host cells, leading to tissue destruction (Sjoberg et al., 2009). Numerous 
complement inhibitory molecules including synthetic compounds, monoclonal antibodies, 
and prokaryotic or eukaryotic proteins inhibit different steps of the complement cascades 
(Morgan and Harris, 2015; Ricklin et al., 2016). Some of these molecules have been used or 
are under development as therapeutics to treat diseases caused by unregulated complement 
activation (Morgan and Harris, 2015; Ricklin et al., 2016). However, because of variation of 
complement proteins across different hosts, most of the complement inhibitory molecules 
developed to target human complement are human- or primate-specific (Jore et al., 2016; 
Kai et al., 1983). With the exception of mice, the investigation of complement-associated 
mechanisms in non-mammalian hosts is very limited.
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One such complement inhibitory molecule is OmCI (also known as conversin), a 17-kDa 
protein that was initially isolated from the saliva of a soft tick species, Ornithodoros 
moubata (Nunn et al., 2005). This protein is believed to protect tick cells/tissues from 
destruction by host complement attack during blood feeding and promote survival of the 
pathogens carried by ticks at the stage of transmission (Fredslund et al., 2008). OmCI binds 
to C5 and prevents its cleavage by C5 convertases (Fredslund et al., 2008; Hepburn et al., 
2007; Jore et al., 2016), which renders tissue damage or pathogen killing by complement of 
mice, rats, guinea pigs, pigs, and humans (Barratt-Due et al., 2013; Barratt-Due et al., 2011; 
Garcia et al., 2013; Hepburn et al., 2007; Jore et al., 2016; Nunn et al., 2005). Therefore, 
OmCI is currently under clinical trials for its use in human complement inhibitory therapy 
and has been commonly utilized to investigate the C5-mediated complement activation in 
mammalian hosts (Barratt-Due et al., 2013; Berends et al., 2015; Blom et al., 2014; Fluiter et 
al., 2014; Garcia et al., 2013; Kuhn et al., 2016; Macpherson et al., 2018; Pischke et al., 
2017). Interestingly, the residues in human C5 involved in OmCI binding bear close identity 
to C5 from avian and mammalian hosts (Jore et al., 2016). This finding raises the possibility 
that OmCI can inhibit the complement from non-mammalian hosts such as Aves. In this 
study, we tested the ability of OmCI to inhibit avian complement-mediated hemolysis and 
have used the Lyme disease bacterium as an example to study the consequences of blocking 
avian-mediated bacterial killing.
2. Material and Methods
2.1 Birds and bacterial strains
American robins (Turdus migratorius) and Gray catbirds (Dumetella carolinensis) were mist 
netted on Block Island, RI from June-August, 2016. Serum was collected from 14 birds (n = 
6 robins; n = 8 catbirds) using BD Microtainer Capillary Blood Collector tubes (Fisher 
Scientific, Hampton, NH). The Borrelia burgdorferi sensu stricto (B. burgdorferi), Borrelia 
duttonii, and Escherichia coli strains used in this study are described in Table S1. The E. coli 
strain BL21 (DE3) was grown in Luria-Bertani broth or agar (BD Bioscience, Franklin 
lakes, NJ), supplemented with antibiotics as described previously (Nazarova and Avaeva, 
1973). All B. burgdorferi and B. duttonii strains were grown in BSK-II completed medium 
with no antibiotics (Barbour, 1984).
2.2 The production of OmCI.
The recombinant OmCI protein was purified in a similar manner as previously described 
(Blom et al., 2014). Briefly, the open reading frames lacking the putative signal sequences of 
omcI with TEC-His6 sequences were codon optimized and synthetized (gift of Dr. 
Strömberg, SOBI, Sweden) and cloned into pET16b vector (Novagen, Merck). The resulting 
plasmid was transformed into E. coli strain BL21 (DE3), which was then induced with IPTG 
for 3h at 30°C. The harvested cells were then suspended into PBS buffer containing 
lysozyme and then lysed by sonication. Subsequently, the inclusion bodies were isolated by 
centrifugation and then solubilized in 6M guanidine hydrochloride in 20 mM Tris-HCl, pH 
8.0 and 10 mM reduced glutathione. The protein was then dialyzed overnight against 20 mM 
Tris-HCl pH 8.0. The refolded OmCI was then applied to Ni-NTA column (Qiagen) and 
eluted using 20 mM Tris, pH 7 with 700 mM imidazole. The pooled fractions with OmCI 
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were then dialyzed against 50 mM Tris-HCl at pH 8.0 with 150 mM NaCl, and stored at 
−70 °C.
2.3 Three-dimensional structure modeling of quail C5d
The structure of C5d from Coturnix quail was modelled according to the crystal structure of 
Human C5d (PDB ID: 5I5K) using the Swiss-Model protein modelling server as described 
(Arnold et al., 2006). The structure of C5d from Coturnix quail is considered as a high-
quality model as the amino acid identity of C5d from human and quail is 55.54 %.
2.4 Hemolytic assays.
The procedure for hemolytic assays was modified from a previously described protocol (Jore 
et al., 2016). Sheep red blood cells previously sensitized by incubating with anti-sheep red 
blood cell stroma antibody in GVB2+ buffer (142 mM NaCl, 50 mM Sodium 5,5-
diethylbarbiturate, 0.1 % gelatin, 0.15 mM CaCl2, 0.5 mM MgCl2, pH 7.35) were obtained 
from Diamedix (Miami Lakes, FL). Next, the cell suspension was incubated with 5 % of 
serum from humans (Complement technology, Inc, Tyler, TX) or Coturnix quail (Canola 
poultry market, Brooklyn, NY) as well as different concentrations of OmCI (2 × 10−11 to 1.6 
× 10−6 M) at 37 °C for 1 h. Subsequently, 100 μl of PBS was added, and the supernatant 
collected by centrifugation was transferred to a 96-well ELISA plate. Plates were read at 405 
nm using a Tecan Sunrise Microplate reader. The supernatant from the cells with GVB2+ 
buffer instead of serum was included as control (no lysis). The supernatant from the cells 
suspended in water was a positive control used for normalization (100 % lysis). To 
determine the concentration of OmCI that inhibits 50 % levels of erythrocyte lysis (IC50) in 
the presence of serum, the data points were fitted using nonlinear regression methods by 
GraphPad Prism software (Version 7, La Jolla, CA).
2.5 Serum resistance assays.
Serum resistance of B. burgdorferi strains B313 and B31-5A4 and B. duttonii strains V and 
LA1 was determined as described previously (Hart et al., 2018; Marcinkiewicz et al., 2019). 
Briefly, the mid-log phase of B. burgdorferi or B. duttonii strains were cultivated in 
triplicate. The resulting spirochete culture was diluted to a final concentration of 5×106 
bacteria per milliliter into BSKII medium without rabbit serum. The cell suspensions were 
then mixed with 40 % of the normal serum from human, Coturnix (quail), Gallus gallus 
(chickens) (Biowest, Riverside, MO), Anser anser (geese) (BioIVT, Hicksville, NY), 
Meleagris gallopavo (turkey) (BioIVT), Turdus migratorius (American robins) or Dumetella 
carolinensis (Gray catbirds) in the presence or absence of OmCI. We also included 
spirochetes mixed with 40 % heat-inactivated (55 °C for 2 h) serum from these animals as 
negative controls for complement-mediated killing. OmCI was used from 0.07 to 6.66 μM 
for human and quail serum and at 2 μM for sera from chickens, geese, turkey, American 
robins, or Gray catbirds. Note that the concentrations of OmCI were greater in this assay, 
compared to that in hemolytic assays described in section 2.4 because the amount of sera 
applied to this assay (40 % of sera) is higher than that in the hemolytic assays (5 %). At 0 
and 4 h after the incubation with serum, an aliquot was taken from each condition and 
counted using a Petroff-Hausser counting chamber (Hausser Scientific, Horsham, PA) and a 
Nikon Eclipse E600 darkfield microscope (Nikon, Melville, NY). We determined the 
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percentage of surviving spirochetes by two independent approaches, motile spirochete 
measuring and Live/Dead staining. For motile spirochete measuring, the number of motile 
spirochetes at 0 and 4 h post incubation with sera was counted under microscopy as 
described (Hart et al., 2018). For Live/Dead staining, spirochetes immediately after mixed 
with sera or incubated with sera for 4h were treated for 15 min with 1× SYBR Green I 
(ThermoFisher) and 6 μM of propidium iodide (ThermoFisher) in 0.5 % BSA in PBS as 
described (Feng et al., 2014; Marcinkiewicz et al., 2019). The live (green) and dead (red) 
spirochetes were visualized by overlaid FITC and Texas Red filters using an Olympus BX51 
fluorescence microscope (Olympus Corporation, Waltham, MA). We then calculated the 
number of live spirochetes at 4 h post incubation normalized to that immediately after 
incubation with serum. Additionally, we determined the concentration of OmCI required to 
inhibit killing by human or quail serum via 50 % (IC50) fitting the data points using 
nonlinear regression methods from GraphPad Prism 7.0 software (GraphPad Software, Inc., 
San Diego, CA).
2.6 Statistical analysis.
Significant differences between samples were determined using a one-way ANOVA with 
post hoc Dunn’s test using GraphPad Prism 7.0 Software. P-values were determined for each 
sample. A P-value < 0.05 (*) was considered to be significant.
3. Results
3.1 OmCI inhibits the ability of quail complement to lyse red blood cells.
The high resolution structure of OmCI with human C5 indicates the amino acids on C5d 
fragment involved in the binding to OmCI, and these residues are conserved across different 
mammalian species (Fig. 1A) (Jore et al., 2016). We observed that these amino acids are 
also highly conserved in C5 from multiple avian hosts including quail and chicken (Fig. 1A). 
Similarly, when building the tertiary structure modelling of quail C5d using human C5d as a 
template, the topography of the amino acids from human C5d critical for OmCI-binding is 
nearly identical to that of the corresponding residues from quail C5d (Fig. 1B). These results 
raise the possibility that OmCI may inhibit avian complement. We thus used quail serum as 
a model to evaluate this protein’s ability to inhibit quail complement-mediated erythrocyte 
lysis. Antibody-sensitized sheep erythrocytes were incubated with sera from quail (or 
humans, as a positive control) containing different concentrations of recombinant OmCI. In 
the absence of OmCI, close to 100 % of the erythrocytes incubated with human serum were 
lysed whereas red blood cells in PBS buffer (control) displayed undetectable lysis (Fig. 2). 
The addition of OmCI to serum reduced the percent lysis of those cells in a dose dependent 
manner (IC50= 6.80 ± 1.07 nM) (Fig. 2), consistent with the ability of OmCI to inhibit 
human complement (Nunn et al., 2005). Quail serum added to erythrocytes in the absence of 
OmCI resulted in more than 90 % lysis (Fig. 2). However, OmCI inhibited sheep red blood 
cell lysis in a dose-dependent manner, suggesting that this protein inhibits quail complement 
(IC50 = 7.15 ± 0.61 nM) (Fig. 2).
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3.2 OmCI reduces the capability of the quail serum to eradicate a serum sensitive B. 
burgdorferi strain.
We next verified the ability of OmCI to inhibit human complement-mediated bacterial 
killing. Calculating the number of motile cells and determining the live cells by Live/Dead 
staining using dark field microscope are two most common approaches to measure 
complement’s ability to kill bacteria. We thus initially utilized a Lyme disease causing 
bacterium, B. burgdorferi, as a model bacterium to verify the ability of OmCI in inhibiting 
spirochete killing by complement. These sera at a final concentration of 40 % containing 
different concentrations of OmCI were incubated with a high passage, non-pathogenic, and 
serum sensitive B. burgdorferi strain B313. We also included a low passage, pathogenic, and 
serum resistant B. burgdorferi strain B31-5A4 as a control. When measuring spirochete 
viability by counting the percentage of motile bacteria under microscopy, we found that 
more than 95 % of strain B31-5A4 survives in untreated or heat-treated human sera, 
independent on the presence of OmCI (Fig. S1). Similarly, close to 95 % of strain B313 was 
detected motile in heat-treated human sera, in the presence or absence of OmCI (Fig. S1). 
Though greater than 95 % of this strain was motile in untreated human sera in the presence 
OmCI, merely 30 % of strain B313 were motile in untreated human sera in the absence of 
OmCI (Fig. S1). These results indicate that OmCI inhibits human complement-mediated 
bacterial killing. Further, there was no statistical difference in percent survival determined 
by Live/Dead staining, compared to that by calculating motile spirochete using dark field 
microscopy (Fig. S1). Though there is a caveat that non-motile bacteria may still be alive, 
our results suggest that the viability and motility of Lyme borreliae in this experimental 
setup are nearly equivalent. As calculating the percentage of motile spirochete was a state-
of-the-art approach to quantitatively determine Lyme borreliae viability (Garcia et al., 2016; 
Hart et al., 2018; Marcinkiewicz et al., 2017; Marcinkiewicz et al., 2019; Wang et al., 2002), 
we evaluated spirochete survival in the following work using this approach.
We next compared the efficacy of OmCI in inhibiting bacterial killing mediated by quail and 
human sera (control) by mixing spirochetes with each of these sera in the presence of 
different concentrations of OmCI. In the absence of OmCI, more than 90 % of strain 
B31-5A4 survived in either untreated or heat-treated human serum, consistent with previous 
studies (Hart et al., 2018; Marcinkiewicz et al., 2019) (Fig. 3A, C, and E). The presence of 
OmCI in sera did not impact survival (Fig. 3A, C, and E). Similarly, strain B313 showed 
approximately 98 % survival in heat-treated human serum, which was not altered by the 
addition of OmCI (Fig. 3A, C, and E). However, less than 20 % of this strain survived in 
untreated human serum in the absence of OmCI; survival of B313 increased in the presence 
of increasing concentrations of OmCI (IC50 = 3.78 ± 1.71 μM) (Fig. 3A, C, and E). These 
results indicate that OmCI can block human serum-mediated killing of a serum sensitive 
Lyme borreliae strain. Furthermore, close to 95 % of strain B31-5A4 was found to survive in 
either untreated or heat-treated quail serum in the absence of OmCI, and this survival was 
independent of the presence of OmCI (Fig. 3B, D, and F). Close to 100 % of strain B313 
was viable in the heat-treated quail serum whether or not OmCI was present (Fig. 3B, D, and 
F). Conversely, only 25 % of this strain remained motile in untreated quail serum in the 
absence of OmCI, in agreement with previous findings (Hart et al., 2018; Marcinkiewicz et 
al., 2019) (Fig. 3B, D, and F). The addition of OmCI increased survival of strain B313 in a 
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dose dependent manner. (Fig. 3B, D, and F). These findings indicate that OmCI prevents 
killing of a serum sensitive Lyme borreliae strain by quail complement.
3.3 OmCI inhibits the killing of a serum sensitive B. burgdorferi strain by the sera from 
different domestic and wild birds.
To examine if OmCI can block complement-mediated bacterial killing of a serum sensitive 
B. burgdorferi strain by sera from additional avian hosts, we tested sera from domestic birds 
including chicken, geese, and turkey, and wild Aves including American robins and Gray 
catbirds. Sera samples from these species were serologically verified for non-infectious 
status of Lyme disease bacteria as described (data not shown) (Hart et al., 2018; 
Marcinkiewicz et al., 2019). We then incubated each of these avian sera with B. burgdorferi 
strains B31-5A4 or B313 in the presence or absence of OmCI. In the absence of OmCI, 
greater than 90 % of the strain B31-5A4 survived in either untreated or heat-treated serum 
from all tested avian hosts (Fig. 4A to F, left panel); survival was not altered by the presence 
of OmCI (Fig. 4A to F, left panel). The results derived from quail sera in Fig. 3 were 
included as control (Fig. 4A). Though close to 100 % of strain B313 survived in heat-treated 
avian sera, less than 20 % of this strain was found motile in the untreated sera from each 
tested avian host. These results suggest the inability of strain B313 to evade avian 
complement (Fig. 4, right panel). The presence of OmCI in untreated sera permitted greater 
than 90 % survival of strain B313 (Fig. 4, right panel). As expected, bacteria survived 
greater than 90 % in heat treated sera and were not affected by the presence of OmCI. Note 
that the relapsing fever spirochete Borrelia duttonii can be transmitted from Ornithodoros 
moubata ticks to humans or potentially to chicken (Elbir et al., 2013; McCall et al., 2007). 
We thus also included two B. duttonii strains in this study and found that both strains 
survived in human or chicken sera at levels of nearly 100 %, independent of heat or OmCI 
treatment (Fig. S2). As no serum sensitive B. duttonii strains are currently available, our 
finding strongly suggests the need of using a serum sensitive Borrelia strain (e.g. B. 
burgdorferi B313) as a tool to examine OmCI-mediated inhibition of bacterial killing. Taken 
together, using B. burgdorferi B313 as a model, we showed that OmCI can block 
complement-dependent bacterial killing in the sera of a variety of Aves.
4. Discussion
Complement is a pivotal host innate immune defense mechanism in the vertebrates’ blood to 
eradicate the non-self-cells (Meri, 2016; Trouw et al., 2017; Zipfel and Skerka, 2009). 
Blood-feeding arthropods such as ticks generate a variety of proteins in their saliva to 
prevent damage to their own cells caused by attack from host complement in a blood meal 
(Chmelar et al., 2016a; Chmelar et al., 2016b; Francischetti et al., 2009; Nuttall, 2019; 
Valenzuela et al., 2000). One of these proteins, OmCI, inhibit complement from diverse 
mammalian species, which prevents tissue damage caused by complement activation (Fluiter 
et al., 2014; Pischke et al., 2017; Roversi et al., 2013). Unlike other tick salivary proteins 
that display mammalian or primate-specific complement inhibition (Jore et al., 2016), we 
found that OmCI prevents erythrocyte lysis mediated avian complement. OmCI is produced 
by O. moubata ticks, which feed on humans and domestic and wild swine, as well as poultry 
such as chickens (Elbir et al., 2013; McCall et al., 2007). Our results thus support the 
Frye et al. Page 7
Ticks Tick Borne Dis. Author manuscript; available in PMC 2021 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
possibility that OmCI prevents potential tissue damage during blood feeding of ticks on 
avian hosts, illustrating the co-evolution between a tick salivary protein and the hosts that the 
tick parasitizes. Further, O. moubata can carry and transmit pathogens, including B. duttonii 
and African Swine Fever viruses (Burrage, 2013; Dixon et al., 2019; Dworkin et al., 2008; 
Talagrand-Reboul et al., 2018). Thus, there is a possibility that OmCI facilitates the 
transmission of these pathogens from ticks to vertebrates by inhibiting complement-
mediated bactericidal activity (Nunn et al., 2005). However, no serum sensitive and O. 
moubata-transmitted pathogens were reported, indicating the limitations of using these 
pathogens to test such a possibility. Furthermore, some of O. moubata-transmitted pathogens 
including B. duttonii use OmCI-independent strategies to evade complement (e.g. producing 
complement inhibitory proteins) (Arias et al., 2017; Hovis et al., 2004; Meri et al., 2006; 
Rossmann et al., 2007). This caveat increases the complexity to delineate the phenotypes of 
these pathogens’ tick-to-host transmission conferred by OmCI, which warrants further 
investigations.
Numerous anti-complement proteins have been identified to inhibit mammalian 
complement, allowing them to be used as tools to tackle the molecular mechanisms of 
human complement activation or a pathogen’s complement evading strategies (Morgan and 
Harris, 2015; Ricklin et al., 2016). However, the sequences of complement proteins varying 
among different vertebrates often render the possibility in using those anti-complement 
proteins to investigate the functions of non-mammalian complement (Kai et al., 1983; Kai et 
al., 1985; Mavroidis et al., 1995; Vogel and Muller-Eberhard, 1985). Many microbes such as 
Lyme borreliae survive in bird sera or can be carried by Aves, highlighting the need to 
identify a tool to study avian complement evasion of these microorganisms (Kurtenbach et 
al., 2002; Tufts et al., 2019). We demonstrated that OmCI blocks complement from avian 
hosts and promotes the survival of a serum sensitive Lyme borreliae strain in the sera from 
different domestic and wild birds. These findings thus illustrate an innovative use of OmCI 
and this bacteria strain as a model to perform mechanistic study of avian complement 
activation and pathogen evasion to that complement.
5. Conclusions
In this study, we demonstrated that a tick salivary protein, OmCI, can inhibit not only human 
but also avian complement-mediated hemolysis. We further used Lyme disease bacteria as a 
model to demonstrate that OmCI-mediated avian complement inhibition facilitates bacteria 
evading the complement-mediated killing. It is noteworthy that B. burgdorferi is transmitted 
by the hard tick species Ixodes rather than the soft tick O. moubata, from which OmCI was 
derived (Radolf et al., 2012; Steere et al., 2016). Thus, our observation here does not suggest 
the role of this protein to facilitate the transmission of Lyme disease bacteria from O. 
moubcitci ticks to avian hosts. Instead, the information derived from this study provides a 
useful tool to inhibit avian complement, which could contribute to the novel insights into 
bird innate immune defense mechanisms and pathogens’ ability to evade bird complement.
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Figure 1. Comparison of primary and tertiary structure of OmCI-binding site on C5 among 
avian and mammalian hosts.
(A) Shown is the alignment of partial amino acid sequences of C5 from Peromyscus 
leucopus mouse (white-footed mouse), Mus musculus mouse (house mouse), rat, human, 
rabbit, horse, pig, chicken, and quail analyzed by ClustalW. The amino acids of human C5 
that make contact with OmCI in the crystal structures shown previously (Jore et al., 2016) 
are highlighted by red squares. (B) The crystal structure of human C5d (5I5K, residues 
932-1372 of human C5) is shown in gray ribbons, and the amino acids involved in binding 
to OmCI are shown and labeled. The modelled structure of Coturnix quail C5d is indicated 
(residues 930-1370 of quail C5) as purple ribbons. The quail C5d amino acids corresponding 
with the residues of human C5d that bind to OmCI are shown and labelled. Graphics were 
generated using Swiss PDB Viewer (Guex and Peitsch, 1997). The amino acids labelled in 
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yellow are conserved between human and quail C5, whereas the amino acids that vary 
between these animals’ C5 are shown in red.
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Figure 2. OmCI inhibits the ability of human and quail complement to initiate antibody-
mediated erythrocyte lysis.
Sheep erythrocytes previously treated with anti-erythrocyte antibody were incubated with 
indicated concentrations of OmCI as well as human or quail serum with a final concentration 
as 5 % or PBS buffer (control) for 1 h. The levels of erythrocyte lysis were evaluated by 
measuring the absorbance at 405 nm of the supernatant from the reactions. The absorbance 
values at 405 nm of each reaction were normalized to that obtained from incubating these 
erythrocytes with water in the absence of OmCI. The work was performed on three 
independent experiments; within each experiment, samples were run in triplicate. The result 
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shown here is the experiment (A) 1, (B) 2, and (C) 3 from the average percent lysis ± 
standard deviation of three replicates in each experiment. The concentration of OmCI to 
inhibit 50 % of erythrocyte lysis (IC50) in the presence of human (blue) and quail (red) 
serum was obtained by fitting the data points using nonlinear regression methods (IC50 = 
6.80 ± 1.07 nM for human serum, IC50 = 7.15 ± 0.61 nM for quail serum).
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Figure 3. OmCI inhibits the ability of human and quail serum to kill a serum sensitive B. 
burgdorferi strain in a dose dependent manner.
A low passage, infectious, and serum resistant B. burgdorferi strain B31-5A4 (“B31-5A4”) 
or a high passage, non-infectious, and serum sensitive B. burgdorferi strain B313 (“B313”) 
was incubated for 4h with indicated concentrations of OmCI as well as (A, C, and E) 
human or (B, D, and F) quail serum with a final concentration of 40 %. Heat-inactivated 
human or quail serum was included as controls. The number of motile spirochetes was then 
assessed microscopically. The percentage of survival for those B. burgdorferi strains was 
calculated using the number of mobile spirochetes at 4 h post incubation normalized to that 
prior to the incubation with serum. The work was performed on three independent 
experiments; within each experiment, samples were run in triplicate. The result shown here 
is the experiment (A and B) 1, (C and D) 2, and (E and F) 3 from the average survival 
percentage ± standard deviation of three replicates in each experiment. The concentration of 
OmCI to inhibit 50 % levels of serum killing (IC50) was obtained by fitting the data points 
using nonlinear regression methods (IC50 = 3.78 ± 1.71 μM for human serum, IC50 = 2.94 
± 0.83 μM for quail serum).
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Figure 4. OmCI reduces the ability of serum from domestic and wild avian hosts to eradicate a 
serum sensitive B. burgdorferi strain.
A low passage, infectious, and serum resistant B. burgdorferi strain B31-5A4 (“B31-5A4”) 
or a high passage, a non-infectious, and serum sensitive B. burgdorferi strain B313 (“B313”) 
was incubated for 4h with the serum from (A) Coturnix quail (“quail”), (B) chicken, (C) 
geese, (D) turkey, (E) American robins (“robins”), or (F) Gray catbirds (“catbirds”) at a final 
concentration of 40 % in the presence (“OmCI-serum”) or absence (“serum”) of 2 μM of 
OmCI. Note that the results from quail were derived from Figure 3. The heat-inactivated 
serum from the above-mentioned animals was included as a control (“heat-treated”). The 
number of motile spirochetes was assessed microscopically. The percentage of survival for 
those B. burgdorferi strains was calculated using the number of mobile spirochetes at 4 h 
post incubation normalized to that prior to the incubation with serum. The experiments were 
performed on three independent experiments; within each experiment, samples were run in 
triplicate, and the survive percentage for each experiment was calculated by averaging the 
results from triplicate experiments. The result shown here is the average ± standard deviation 
of the survival percentage from three independent experiments. (*), the significant difference 
(P < 0.05) of the percent survival of spirochetes between indicated groups was determined 
using the one-way ANOVA with post hoc Dunn’s test.
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